PDX regulates inflammatory cell infiltration via resident macrophage in LPS-induced lung injury

Area of Science:

• Immunology
• Pulmonology
• Lipid Mediator Biology

Background:

• Inflammatory cell infiltration is a key factor in acute respiratory distress syndrome (ARDS) pathogenesis.
• Protectin DX (PDX), an endogenous lipid mediator, possesses anti-inflammatory and pro-resolution properties.

Purpose of the Study:

• To investigate the protective effects of Protectin DX (PDX) against lipopolysaccharide (LPS)-induced lung injury.
• To elucidate the mechanisms by which PDX modulates inflammatory cell recruitment in ARDS.

Main Methods:

• In vivo studies involved LPS administration in mice followed by PDX treatment, with inflammatory cell counts assessed by flow cytometry.
• Macrophage depletion was achieved using clodronate liposomes.
• Gene and protein expression analysis (RT-PCR, ELISA) measured inflammatory markers like MIP-2, MCP-1, TNF-α, and MMP9.
• In vitro experiments assessed chemokine receptor expression on neutrophils and macrophages exposed to LPS and PDX.

Main Results:

• PDX treatment attenuated LPS-induced lung injury.
• PDX inhibited the recruitment of neutrophils and macrophages to the lungs.
• PDX repressed resident macrophage expression and release of MCP-1 and MIP-2, key chemokines for inflammatory cell recruitment.
• PDX's inhibition of neutrophil infiltration was linked to the TNF-α/MIP-2/MMP9 signaling pathway.

Conclusions:

• Protectin DX (PDX) mitigates LPS-induced lung injury by reducing inflammatory cell recruitment.
• PDX exerts its protective effects, in part, by modulating resident macrophage chemokine production.
• These findings highlight PDX as a potential therapeutic agent for ARDS by targeting inflammatory cell infiltration.